Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non-Current Assets (2016 - 2025)

Arrowhead Pharmaceuticals' Other Non-Current Assets history spans 16 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 54.23% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, down 54.23%, while the annual FY2025 figure was $1.4 million, 69.01% down from the prior year.
  • Other Non-Current Assets reached $1.4 million in Q4 2025 per ARWR's latest filing, up from $1.4 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $4.5 million in Q3 2024 to a low of $210000.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $1.2 million, with a median of $274000.0 recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: surged 2023.81% in 2024, then crashed 69.66% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $273000.0 in 2021, then fell by 23.08% to $210000.0 in 2022, then rose by 10.48% to $232000.0 in 2023, then surged by 1228.88% to $3.1 million in 2024, then crashed by 54.23% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Other Non-Current Assets are $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025).